#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
The article argues that cannabis terpenes, the volatile aromatic compounds that give cannabis its distinct flavor and aroma profiles, play a significant role in determining the plant’s therapeutic effects and may be equally or more important than THC content alone in predicting clinical outcomes. Terpenes such as myrcene, limonene, and pinene have individual pharmacological properties and modulate the effects of cannabinoids through the “entourage effect,” a phenomenon whereby multiple plant compounds work synergistically to produce combined therapeutic benefits. Current dispensary labeling and consumer purchasing practices typically emphasize THC percentages while largely ignoring terpene profiles, potentially leading patients and clinicians to make suboptimal product selections for specific therapeutic goals like pain relief, anxiety reduction, or sleep improvement. Understanding terpene composition could allow clinicians and patients to make more informed choices about which cannabis products are likely to produce desired effects for their particular conditions, moving beyond the reductionist approach of selecting products based solely on THC content. Clinicians counseling patients on cannabis use should ask about or review the terpene profile alongside cannabinoid testing to better predict efficacy and tailor recommendations to individual patient needs and conditions.
“When patients come in asking for the highest THC percentage, I redirect them to the terpene profile because that’s what actually determines whether they’ll have therapeutic benefit or side effects. A 15% THC flower with beneficial terpenes like myrcene and limonene will outperform a 25% THC product lacking those compounds, and this is something we’re finally seeing validated in the literature.”
🧠 While terpene profiling of cannabis products has gained considerable attention in popular media and marketing, the clinical evidence supporting the superiority of terpene content over THC potency remains limited and largely anecdotal. Terpenes—aromatic compounds like limonene, myrcene, and pinene—do have documented pharmacological properties and may modulate cannabis effects through entourage mechanisms, yet well-controlled human trials directly comparing terpene profiles to THC dosing are sparse. Current dispensary labeling practices vary widely in accuracy and standardization, making it difficult for patients to reliably use terpene information for informed decision-making. Rather than positioning terpenes as uniformly “more important” than THC content, clinicians should acknowledge that individual cannabinoid and terpene responses are highly variable and that THC quantification remains a more standardized, measurable parameter for dose-related safety counseling. When
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
